Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yolanda Masunu"'
Autor:
Richard Brostrom, W Thane Hancock, Stephanie Kern-Allely, Haley Cash McGinley, Ashley Tippins, Carter Apaisam, Merlyn Basilius, Michele Leon Guerrero, Yolanda Masunu, Heather Pangelinan, Daisy Pedro, Peter Judicpa
Publikováno v:
BMJ Public Health, Vol 1, Iss 1 (2023)
Introduction The US-affiliated Pacific Islands (USAPI) are six geographically isolated and culturally distinct Pacific Island jurisdictions with special relationships with the USA; the USAPI were included in the US COVID-19 vaccination effort. This s
Externí odkaz:
https://doaj.org/article/f923ed4311f7460183eec8a4f1346beb
Autor:
Ashley Tippins, Neil Murthy, Mehreen Meghani, Amy Solsman, Carter Apaisam, Merlyn Basilius, Maribeth Eckert, Peter Judicpa, Yolanda Masunu, Kelsey Pistotnik, Daisy Pedro, Jeremy Sasamoto, J. Michael Underwood
Publikováno v:
Morbidity and Mortality Weekly Report
Vaccine-preventable diseases (VPDs) cause substantial morbidity and mortality in the United States Affiliated Pacific Islands (USAPI).* CDC collaborates with USAPI immunization programs to monitor vaccination coverage. In 2016, † USAPI immunization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cad8551d0c654042b627ffceba1e1f61
https://doi.org/10.15585/mmwr.mm6720a3
https://doi.org/10.15585/mmwr.mm6720a3
Autor:
Roxanne E. Williams, Preeta K. Kutty, Yolanda Masunu-Faleafaga, Abdirahman Mahamud, Nobia J. Williams, Eyasu H. Teshale, Theresa M. Dulski, William J. Bellini, Philip Garcia, Laura Walls
Publikováno v:
Vaccine. 31:3683-3687
Introduction In line with the global goals for measles elimination, countries in the West Pacific Region (WPR) have set a goal to eliminate measles by 2012. Due to its contagiousness, high population immunity is needed for achieving and documenting m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01695abeec8fbf8abc4cfde26a3c2ca7
https://doi.org/10.1016/j.vaccine.2013.05.102
https://doi.org/10.1016/j.vaccine.2013.05.102
Autor:
Yolanda Masunu-Faleafaga, Eyasu H. Teshale, Theresa Dulski, Jan Drobeniuc, Roxanne E. Williams, Abdirahaman Mahamud, Philip R. Spradling, Jian Xing
Publikováno v:
Clinical and Vaccine Immunology. 20:559-561
Most persons who receive hepatitis B vaccine during infancy will have a level of antibody to hepatitis B surface antigen (anti-HBsAg) of P < 0.001). The presence of any detectable anti-HBsAg among persons vaccinated in the remote past may indicate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2f5a76e81458371555fa8817ed9d8c1
https://doi.org/10.1128/cvi.00694-12
https://doi.org/10.1128/cvi.00694-12